Bone quality: A perspective from the Food and Drug Administration

Current Osteoporosis Reports

Volumn 4, Issue 2, 2006, Pages 76-79

  Kehoe, Theresa ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ETIDRONIC ACID; FLUORIDE SODIUM; VITAMIN D;

BIOMECHANICS; BONE DENSITY; BONE STRUCTURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DUAL ENERGY X RAY ABSORPTIOMETRY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMAGING SYSTEM; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CONTROLLED CLINICAL TRIALS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33750338870     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-006-0006-5     Document Type: Review

References (9)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy [review]. JAMA 2001, 285:785-795.
2. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045.
3. Capron A, Donaldson S, Raisz LG, Swift S: Osteoporosis panel summary. J Bone Miner Res 2003, 18:1160-1162. This article summarizes a collection of articles in the Journal of Bone and Mineral Research that encapsulates the presentations and discussions from the June, 2002, National Institutes of Health conference on study design and ethical considerations for osteoporosis drug development trials.
4. US Food and Drug Administration, Center for Drug Evaluation and Research: Endocrinologic and Metabolic Drugs Advisory Committee meeting documents. Silver Spring, MD, September 25, 2002. http://www.fda.gov/ohrms/dockets/ac/cder02. htm#EndocrinologicMetabolicDrugs. Accessed January 21, 2006.
5. Temple RJ: A regulatory authority's opinion about surrogate endpoints. In Clinical Measurement in Drug Evaluation. Edited by Nimmo WS and Tucker GT. New York: John Wiley & Sons; 1995:3-22. This chapter provides an overview of surrogate endpoints in the drug approval process. It focuses mainly on endpoints related to cardiovascular outcomes.
6. Colman EG: The Food And Drug Administration's osteoporosis guidance document: past, present, and future. J Bone Miner Res 2003, 18:1125-1128. This article provides a comprehensive history of the FDA's guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of osteoporosis.
7. Riggs BL, Hodgon SF, O'Fallon WM, et al.: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802-809.
8. Harris ST, Watts NB, Jackson RD, et al.: Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993, 95:557-567.
9. US Food and Drug Administration, Center for Drug Evaluation and Research, Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. http://www.fda.gov/Cder/ guidance/osteo.pdf.